Following a limited submission
AWMSG advice |
|||
| Status: Recommended with restrictions | |||
Azithromycin (Zedbac®) 500 mg powder for solution for infusion is recommended as an option for restricted use within NHS Wales. Azithromycin (Zedbac®) 500 mg powder for solution for infusion should be restricted for use within NHS Wales for the treatment of community-acquired pneumonia (CAP) due to susceptible microorganisms, in adult patients where initial intravenous therapy is required. Azithromycin (Zedbac®) 500 mg powder for solution for infusion is not recommended for use within NHS Wales for the treatment of pelvic inflammatory disease (PID) due to susceptible microorganisms, in patients where initial intravenous therapy is required. |
|||
|
|||
Medicine details |
|||
| Medicine name | azithromycin (Zedbac®) | ||
| Formulation | 500 mg powder for solution for infusion | ||
| Reference number | 2476 | ||
| Indication | Treatment of community-acquired pneumonia due to susceptible microorganisms in adult patients where initial intravenous therapy is required. Treatment of pelvic inflammatory disease due to susceptible microorganisms in patients where initial intravenous therapy is required. Consideration should be given to official guidance regarding the appropriate use of antibacterial agents |
||
| Company | Aspire Pharma Ltd | ||
| BNF chapter | Infections | ||
| Submission type | Limited | ||
| Status | Recommended with restrictions | ||
| Advice number | 1914 | ||
| NMG meeting date | 18/06/2014 | ||
| AWMSG meeting date | 16/07/2014 | ||
| Ratification by Welsh Government | 13/08/2014 | ||
| Date of issue | 14/08/2014 | ||
| Date of last review | 29/09/2017 | ||